They only moved the OSA/cannaboids program to Australia only. The GABA program with KRM-II-81 is the one in NIH preclinical trials and has shown significant potential which hopefully leads to multiple development deals/paths for epilepsy and various forms of pain management. The CEO interview in March highlighted how confident they are becoming in this drug candidate as it is now in the final tier 3 stage of NIH where they are supposedly looking at specific pain models/indications and directly testing addictive liability in animals. If these results continue to confirm their past work and all inference studies, then this will be an absolute monster winner.
Timing of when they wrap up the tier 3 preclinicals is unknown, but the CEO implied it was an "intermediate" step and hoping to open pursestrings in the shorter term.
News 
Market Data 
Discover 
AI
